SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive data from a phase I trial of lead product candidate SGN-40, demonstrating that it exhibits durable objective responses and is well-tolerated in patients with non-Hodgkin’s lymphoma (NHL) who have failed multiple prior therapies. Another phase I study showed SGN-40 induces antitumor activity, is well-tolerated and a maximum tolerated dose has not been reached in patients with relapsed multiple myeloma. The data were reported today at the American Society of Hematology (ASH) 48th Annual Meeting and Exposition in Orlando, Florida.
